بهترین پزشکان برای معالجه فوق العاده بیماران
Doctor sahar shojaei

Sahar Shojaei

Biography

Sahar Shojaei, PhD

 

Present title & Affiliation

Primary Appointment:

Founder and Chairman of board in Middle East Gene Therapy Co., National Institute of Genetic Engineering and Biotechnology, Tehran, Iran

Education & Training

Degree-Granting Education

October 2010- June 2014: PhD in Biology-Molecular Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

October 2008 – September 2010: MSc in Molecular Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

October 2004 – September 2008: BSc in Cellular and Molecular biology-Genetics, Shahed University, Tehran, Iran.

Expert Training

Clinical trial Documentation

Cell therapy FDA regulations

Gene therapy FDA regulations

Honors & Awards

1.Tird Rank of Razi festival in health technology and invention in IRAN

2-Top inventor in Stem cell and regenerative medicine in IRAN in 2018

  1. Doctoral Comprehensive exam degree: 20
  2. Third grade in Kharazmi Festival in 2007, Tehran/Iran
  3. First grade student in Olympics of Biology Students.
  4. First grade for presenting a poster presentation in “The Third Congress on Basic Theoretical of Stem Cell”, Shiraz University, 2009. Shiraz/Iran.
  5. 19 th grade in competition exam for Msc Entrance, National Institute of Genetic Engineering, Tehran/Iran.
  6. Third grade competition exam for PhD Entrance, National Institute of Genetic Engineering, Tehran/Iran.
  7. First grade for presenting (The best speech award) an oral presentation in “The Third Congress on Breast cancer disease”, Tehran University, 2009. Shiraz/Iran.

Exprience and Services

Books

Apoptosis principles in generation and treatment of disease. Bibliography and editing by Sahar Shojaei, Reza Yarani, Kamran Mansori, Lila Farhadi. Supervisor Dr. Majidzadeh. 2014.

Molecular Aspects of Breast Cancer. Bibliography and editing by Sahar Shojaei, Naghmeh Gholipor, Zeinab Emrozi and Yegane Eshaghkhani et al. Supervisor Dr. Bakhto. 2014

Clinical cytogenetics. Translated by Nazanin jalilian, Sahar Shojaei, Yegane Eshaghkhani, Naghme Gholipor, et al. Supervisor Dr.Tabrizi. 2014

Selected Publications

Mehran Moradi Farsani, Naghmeh Bahrami, Sahar Shojaei*. Journal of Craniomaxillofacial Research 2017. 4(3):383-386.  Gene therapy a new approach in dentistry: human or microbial gene modification

M. Gardaneh, S. Shojaei, A. Rahimi Shamabadi & P. Akbari (2018) Breast Cancer Cell  Apoptosis is Synergistically Induced by Curcumin, Trastuzumab, and Glutathione Peroxidase-1 but Robustly Inhibited by Glial Cell Line-Derived Neurotrophic Factor, Nutrition and Cancer, 70:2, 288-296, DOI: 10.1080/01635581.2018.1412486

Mossa Gardaneh, Sahar Shojaei, Ahmad Kaviani, Babak Behnam. GDNF induces RET–SRC–HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells. Breast Cancer Research and Treatment. 2017, V 162, Issue 2 , pp 231–241

Mohammad Bayat, Sahar Shojaei, Naghmeh Bahrami, Abdolreza Mohamadnia, Pegah Shojaei, Naeim Bahrami. Protein engineering of recombinant human bone morphogenetic protein 2 with higher interaction with Ca phosphate based scaffold used for osteogenesis. Journal of biomedical Material Research. 2017, DOI: 10.1002/jbm.a.36143.

Shojaei S, Gardaneh M (2012) Maximum inhibition of breast cancer/stem cellgrowth by concomitant blockage of key receptors. Journal of Medical Hypotheses and Ideas 6:44-49. DOI: http://dx.doi.org/10.1016/j.jmhi.2012.06.001 .

Shojaei S, Gardaneh M, Rahimi Shamabadi A (2012) Target points in trastuzumab resistance. International Journal of Breast Cancer Article ID: 761917, 9 pages, DOI:10.1155/2012/761917.

Shojaei S, Gardaneh M (2011) Expression of monoclonal antibody herceptin in human cell lines and analysis of Her2 reduction in breast cancer cell lines. Iranian Journal of Breast Diseases 4:12-18.

Gardaneh M, Panahi Y, Shojaei S, Mazaheri-Tehrani E, Maghsudi N (2010) Neuroprotection in Parkinson’s Disease: a multi-directional genetic strategy for maximum protection of dopaminergic neurons against parkinsonian toxicity. Iran J Med Hypotheses Ideas. 4: 7-19.

Contact Me